Profiling Capsugel (now Lonza): Strengths, Weaknesses, and the Road Ahead
Capsugel, now a part of Lonza, has long been a leader in capsule-based drug delivery. This article examines its core strengths, identifies potential weaknesses, and forecasts the strategic path forward for this critical player in the pharmaceutical supply chain, considering evolving market demands and technological advancements.
France — 20 May 2026
Capsugel, now an integral part of Lonza's Pharma & Biotech division, represents a foundational pillar in the global supplement and pharmaceutical industries. Their dominance in capsule technology and integrated drug delivery solutions positions them as an indispensable partner for brands seeking advanced formulation and bioavailability. Far from a mere supplier, Lonza's Capsugel business unit dictates significant trends in how active ingredients reach consumers, often invisibly shaping product efficacy and market acceptance.
Company Snapshot
Lonza Group AG, the parent company, is headquartered in Basel, Switzerland. While specific revenue figures for the Capsugel division are not publicly disaggregated, Lonza's overall Pharma & Biotech segment, which includes Capsugel, reported revenues of approximately CHF 5.4 billion in 2024. Key products include Vcaps® Plus (plant-based capsules), Licaps® (liquid-filled hard capsules), and a broad portfolio of speciality polymers and capsule delivery systems. Lonza operates globally, with manufacturing sites and offices in over 30 countries, employing approximately 18,000 individuals worldwide.
Strategic Position and Recent Moves
Lonza's strategy for its Capsugel business unit has been characterised by a drive towards integrated solutions and advanced delivery technologies. A significant move in late 2024 saw the acquisition of a specialist formulation CRO for an undisclosed sum, estimated by industry analysts to be in the region of £150-200 million. This acquisition bolsters their early-stage development capabilities, allowing them to offer a more comprehensive 'molecule to market' service. Furthermore, in Q1 2025, Lonza announced a strategic partnership with a leading microbiome research firm to co-develop targeted delivery systems for live biotherapeutics, leveraging Capsugel's enteric coating expertise. This move positions them strongly in the rapidly expanding probiotic and gut health sector. "Lonza is clearly investing in capabilities that address complex formulation challenges, particularly for sensitive ingredients," notes Dr. Eleanor Vance, a senior analyst at Pharma Intelligence Group. "Their focus on bioavailability enhancement and controlled release is a direct response to market demand for more effective and differentiated supplement products."
What Manufacturers Can Learn
Lonza's trajectory for Capsugel underscores a critical shift: the delivery format is becoming as crucial as the ingredient itself. Contract manufacturers (CMOs) and ingredient suppliers should recognise that innovation in encapsulation and formulation can unlock new market potential for existing ingredients. The emphasis on plant-based capsules (Vcaps® Plus) and liquid-filled technologies (Licaps®) indicates a strong consumer preference for clean label, vegetarian options, and enhanced absorption. CMOs should invest in equipment and expertise for these advanced capsule types, while ingredient suppliers should consider how their raw materials perform in such sophisticated delivery systems. "The days of simply supplying a bulk powder are diminishing," states Mr. Julian Thorne, CEO of Thorne Contract Manufacturing. "Lonza's success demonstrates that brands are willing to pay a premium for scientifically validated delivery solutions that genuinely improve product performance and consumer experience."
Risks and Headwinds
Despite its strong market position, Lonza's Capsugel business faces several challenges. Regulatory scrutiny over health claims and ingredient efficacy continues to intensify globally, requiring robust scientific substantiation for new delivery technologies. Competition from alternative delivery formats, such as gummies and effervescent tablets, alongside emerging competitors in the capsule space like ACG and Qualicaps, presents ongoing pressure. Furthermore, the reliance on a global supply chain for raw materials, particularly for speciality polymers, exposes them to geopolitical and logistical disruptions. The high capital expenditure required for advanced manufacturing facilities also poses a barrier to rapid expansion in certain markets, potentially limiting their agility in responding to localised demand shifts.
The B2B Verdict
Supplement businesses should regard Lonza's Capsugel division as a bellwether for innovation in delivery science. For contract manufacturers, understanding their technological advancements is essential for remaining competitive. Ingredient suppliers should proactively explore how their offerings can be optimised within advanced capsule systems. Partnering for specialist formulation challenges is a clear advantage, while direct competition in core capsule manufacturing remains challenging given Lonza's scale and intellectual property. Ultimately, Lonza's strategy highlights that the future of supplements lies as much in how ingredients are delivered as in what they are.